ANAB vs IMVT

Analysts rate AnaptysBio, Inc.

(ANAB) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AnaptysBio, Inc.

(ANAB) delivered a total return of +304. 3%, compared to +84. 4% for Immunovant, Inc. (IMVT). Over 10 years, the gap is even starker: ANAB returned +511. 9% versus IMVT's +190. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AnaptysBio, Inc.

(ANAB) is the lower-risk stock at 0. 97β versus Immunovant, Inc. 's 1. 36β — meaning IMVT is approximately 40% more volatile than ANAB relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 38% for AnaptysBio, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: AnaptysBio, Inc.

grew EPS 91. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Immunovant, Inc.

(IMVT) is the more profitable company, earning 0. 0% net margin versus -5. 6% for AnaptysBio, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANAB leads at 20. 4% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — ANAB leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, AnaptysBio, Inc.

(ANAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97), +511. 9% 10Y return). Both have compounded well over 10 years (ANAB: +511. 9%, IMVT: +190. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ANAB is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.